Sequential Genicular Nerve Ablation Prior to Geniculate Artery Embolization in Knee Pain

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorZagazig University

About this trial

The goal of this clinical trial is to evaluate whether performing genicular nerve ablation (GNA) before geniculate artery embolization (GAE) improves pain relief and knee function in patients with chronic knee pain. The main questions it aims to answer are:

* Does performing GNA prior to GAE enhance pain relief, as measured by the Visual Analog Scale (VAS), at 3 months post-procedure? * Does the sequential approach improve knee function as assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)?

Study investigators will compare two groups to see if the sequential approach (GNA followed by GAE) provides better outcomes compared to GAE alone.

Participants will:

* Undergo either sequential GNA followed by GAE or GAE alone * Have their knee pain and function assessed at baseline, 1 month, 3 months, and 6 months post-procedure * Complete a structured patient satisfaction questionnaire (PSQ) at 3 months post-procedure * Be monitored for procedure-related adverse events up to 6 months post-procedure,

Eligibility criteria

Qualifiers

Adults aged 18 to 80 years.

Diagnosed with chronic knee pain refractory to conservative treatment.

Able to provide informed consent.

Agree to follow the study procedures and attend follow-up visits.

Disqualifiers

Contraindications to GNA or GAE procedures (e.g., allergy to local anesthetics, active infection at the procedure site).

Recent knee surgery within the last six months.

Severe comorbid conditions that may interfere with the study outcomes (e.g., rheumatoid arthritis, other severe autoimmune diseases).

Current participation in another clinical trial that could interfere with the outcomes of this study.

Trial design

Treatments tested in this trial

  • GNA followed by GAE
  • GAE alone

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators